Sjogrens

Amgen announced topline results from the Phase 3 OASIZ 301 study showing the efficacy of dazodalibep in Sjögren's dz, w/ signif ESSDAI improvements at wek 48. DAZO is a CD40L antagonist fusion protein https://t.co/5QPBdZivxC https://t.co/tJvYo6TrWO

AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO…

Article

Remission – Believe it or Not (10.2.2026)

Jack Cush, MD Oct 02, 2026

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

Worldwide the Sjögren’s disease market size was valued at approximately $1 billion USD in 2025 and is projected to reach nearly $10 billion USD by 2036 (with annual growth of 26.2% during the forecast period from 2026 to 2036). https://t.co/kxwftpIDeo https://t.co/RnEbzqFi2W

Sjogren’s Syndrome Market Poised for Sustained Growth Amid Advancements in Trea…

Amgen announced topline results from the Phase 3 OASIZ 301 study showing the efficacy of dazodalibep in Sjögren's dz, w/ signif ESSDAI improvements at wek 48. DAZO is a CD40L antagonist fusion protein https://t.co/5QPBdZivxC https://t.co/VfV873Lire

AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO…

Amgen announced topline results from the Phase 3 OASIZ 301 study evaluating dazodalibep (CD40L antagonist fusion protein) in adult Sjögren's dz w/ positive ESSDAI results at wk 48 https://t.co/hBKIdOE9aR https://t.co/y3tXp5xwgC

AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO…

Article

NME: New Molecular Entities (8.28.2026)

Jack Cush, MD Aug 28, 2026

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com. Take this week's RheumIQ and test your knowledge!

Aortic inflammation (Aortopathies) occurs in autoimmune rheumatic diseases (ARD) including Takayasus, #GCA, SLE, RA, AS, SSc, relapsing polychondritis, Cogan’s syndr, Behçet’s, & IgG4-related disease). Dx imaging options: CTA, MRI, & PET/CT. Underlying path may be granulomatous, https://t.co/lKBhEnTcKB

Article

Insights into Sjögren’s Disease - A Rheum Survey

Jack Cush, MD Aug 27, 2026

RheumNow recentlty surveyed rheumatologists about Sjogren’s disease (SjD) - how they approach diagnosis, treatment, and unique challenges; all important as new advances in SjD evolves.

Rheum Survey >> What therapy do you most commonly use to treat Sjogrens disease? Answer here: https://t.co/XJEsqoSlbn

Sjogren's Educational Barriers | RheumNow

Rheum Survey >> What therapy do you most commonly use to treat Sjogrens disease? Answer here: https://t.co/XJEsqoSlbn

Sjogren's Educational Barriers | RheumNow

Study of 154 anti-Ku Ab+ pts (51 IMMM, 46 SLE, 30 Sjögrens, 27 Sc) = 60 (39%) had ILD - 75% progressed; more rapidly in males. BUT Ku+ is rare <4%, not specific, without clear clinical implications. Ku is a myositis-assoc Ab (like Ro52/Ro60, U1-RNP, PM/Scl) https://t.co/s1VFhaOYgn

Interferon-α as an Immunologic Driver of Sjögren's Disease Using data from a Sjogren's registry, researchers have shown that IFNα drives Sjögren's disease, and can be elevated a decade before diagnosis. This study assessed the role of type 1 interferon (IFNα) in its onset and https://t.co/Clj9u5COzQ

Interferon-α as an Immunologic Driver of Sjögren's Disease Using data from a Sjogren's registry, researchers have shown that IFNα drives Sjögren's disease, and can be elevated a decade before diagnosis. This study assessed the role of type 1 interferon (IFNα) in its onset and https://t.co/0BDDvR5cUB

Article

Interferon-α as an Immunologic Driver of Sjögren's Disease

Jack Cush, MD Jul 22, 2026

Using data from a Sjogren's registry, researchers have shown that IFNα drives Sjögren's disease, and

ICYMI: B Cells at the Brink in Sjögren Disease The current issue of Arthritis & Rheumatology reviews current understanding of the immunopathogenesis of Sjögren disease (SjD) and how that has influenced the quest for drug development for this most systemic autoimmune disorder. https://t.co/OBFqHYof5m

Article

ICYMI: B Cells at the Brink in Sjögren Disease

Jack Cush, MD Jun 29, 2026

A recent issue of Arthritis & Rheumatology reviews current understanding of the immunopathogenesis of Sjögren disease (SjD) and how that has influenced the quest for drug development for this most systemic autoimmune disorder.

Article

Do You Zoster Vaccinate? (6.19.2026)

Jack Cush, MD Jun 19, 2026

Dr. Jack Cush reviews the news, journal reports and best ways to review EULAR 2026.

Article

NK Cells Without a CAR: AB-101 Is Neither CAR-T nor CAR-NK

Henrique Dalmolin, MD Jun 11, 2026

Much of the meeting came for the next CAR T readout. AB-101 drew attention for a different reason. It depletes B cells by a completely different route.

Abstr LB0003 Off-the-shelf allogeneic NK cell therapy + rituximab in refractory RA, Sjögren disease, and systemic sclerosis. 31 patients. Outpatient administered. RA at 6 months: 71% ACR50, mean CDAI change −36.8. SSc: 100% rCRISS25 response. SjD: 86% ClinESSDAI responders. https://t.co/60046jgYia

https://x.com/synovialjoints/status/2063222707315974230/photo/1

Interesting data on the effect of AB-101 + RTX on refractory RA, SSc and SjD. Curious about long term results and potential position in tx strategies LB0006 @RheumNow #EULAR2026 https://t.co/opbh8yGmwO

CAR-T without the CAR-T risks? AB-101, an off-the-shelf NK cell therapy + RTX, delivered in refractory RA, Sjögren, and SSc (n=31): RA ACR50 71%, SSc mRSS -9.5, SjD ClinESS DAI -8.6 at 6 mo. Outpatient delivery without CAR-T associated AEs? @RheumNow #EULAR2026 LB0003 https://t.co/xi6ZdLwHcN

https://x.com/JihaRheum/status/2063224633923658191/photo/1

#EULAR2026 LB0003 CAR-T is not scalable. In a Phase 2a of off-the-shelf AB-101 allogenic NK + low dose conditioning (Cyclo & Flud) + Rituximab: preliminary efficacy & safety profile in severe-refractory RA (N=15), SjD (11), SSc (5). Longer FU & Comparator is needed @RheumNow https://t.co/gQniufREQC

Top 5 abst in #SjD #anifrolumab +RCT #ianalumab LTE Rx sustained #telitatacept +LTE #iana improves u/s parotids #TYK2 sig in#SjD OP0002, 0126, 127, 160 POS0284 #EULARbest #EULAR2026 @RheumNow @eular_org

#proof of #concept in #Sjogren’s #dis #lanalumab Treatment reduced in #SjD ✅reduced B cells in #salivary #glands —nearly complete depletion in serum ✅reduced B cell activation ✅improved #inflammation of #parotid & #submandibular glands @RheumNow #EULAR2026 #OP0163 #POS0284

OMRF study: Anti-Ro neg Sjögren’s patients share similar molecular profiling as anti-Ro positive pts: innate immune signaling, immune cell activation, inflammation, autophagy, apoptosis, and metabolic dysregulation pathways #EULAR2026 @RheumNow https://t.co/zJm6EbpyIB